Clinical Trials Logo
  1. Home
  2. Neisseria Meningitidis
  3. NCT01621945

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) — Exten Effivac  

Neisseria Meningitidis Clinical Trial

Official title:
Phase 3, Vaccinal Activity Assessment of MenBVac Against Neisseria Meningitidis B:14,P1.7,16 Strain in Child

Clinical Trial Summary

The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (>= 4), before the fourth dose of MenBvac and after: 6 weeks and one year after the fourth dose.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01621945
Study type Observational
Source University Hospital, Rouen
Contact
Status Completed
Phase Phase 3
Start date April 2012
Completion date September 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT01218451 - NeisVac-C Single Prime Study in Infants Phase 3
Completed NCT00323050 - Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects Phase 3
Completed NCT01090453 - Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants Phase 2
Completed NCT00454987 - Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine Phase 4
Completed NCT00891176 - Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines Phase 3
Completed NCT01839188 - Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) Phase 3
Completed NCT01553279 - Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) Phase 3
Completed NCT00263653 - Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 Phase 3
Completed NCT00772070 - Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine Phase 2
Completed NCT00129116 - 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age Phase 2
Completed NCT00127855 - Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine Phase 2
Completed NCT00871338 - Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants Phase 2
Completed NCT00700635 - Dose Comparison Study of Menactra® in US Children Phase 2
Completed NCT00326118 - Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Phase 3
Completed NCT01730391 - Neisseria Meningitidis Burden of Disease Study N/A
Completed NCT00197795 - Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults Phase 2
Completed NCT00289783 - Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine Phase 3
Completed NCT00444951 - Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia Phase 3
Completed NCT00258700 - Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine Phase 3
Completed NCT03419533 - Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers